B-cell Acute Lymphoblastic Leukemia (B-ALL) Clinical Trial
Official title:
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05397496 -
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT04166838 -
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
|
Early Phase 1 | |
| Withdrawn |
NCT05513612 -
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
|
Phase 1 |